Johnson & Johnson: COVID-19 Booster Dose Generates Strong Antibody Response | Well being Information

Johnson & Johnson reported Wednesday that a second dose of its COVID-19 vaccine produced a “rapid and robust” antibody response.

The company said new preliminary data from its booster shot study showed a nine-fold increase in spike-binding antibodies over the single-shot regimen. The preliminary data have not yet been peer-reviewed or published in a scientific journal.

“A significant increase in binding antibody responses was seen in participants aged 18 to 55 years and those aged 65 and over who received a lower booster dose,” the company said in a press release.

Mathai Mammen, global head of Janssen Research & Development at Johnson & Johnson, said in a statement that the new data shows that “a booster dose of the Johnson & Johnson COVID-19 vaccine can reduce antibody responses in subjects previously receiving further increased our vaccine. “

Coronavirus cartoons

The development comes a week after US health officials announced they would offer booster injections starting this fall. The plan, which initially only applies to Pfizer and Moderna recipients, is subject to third-dose approval by the Food and Drug Administration and the recommendations of the Centers for Disease Control and Prevention’s Vaccine Committee.

U.S. health officials said they believed J&J recipients would also need a booster dose, but wanted to wait for additional dates.

“We look forward to discussing with public health officials a possible strategy for our Johnson & Johnson COVID-19 vaccine, which will be boosted eight months or more after the primary single-dose vaccination,” said Mammen.

The company reported in July that the immune response of its single-dose vaccine lasted eight months and produced a “strong, sustained” immune response to the rapidly spreading Delta variant.

J & J’s press release on Wednesday made no mention of how the booster shot withstood the Delta variant, which is causing a surge in coronavirus cases in the US

Comments are closed.